首页> 外文期刊>CNS drug reviews >A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor.
【24h】

A-85380: a pharmacological probe for the preclinical and clinical investigation of the alphabeta neuronal nicotinic acetylcholine receptor.

机译:A-85380:用于字母神经元烟碱型乙酰胆碱受体的临床前和临床研究的药理探针。

获取原文
获取原文并翻译 | 示例
           

摘要

A-85380 [3-(2(s)-azetidinylmethoxy) pyridine] is a neuronal nicotinic acetylcholine receptor (nAChR) agonist that has been a useful tool in the investigation of the function of nAChRs in both preclinical and clinical studies. Amongst nAChR subtypes, A-85380 shows selectivity for the alpha(4)beta(2) vs. the alpha(7) or alpha(1)beta(1)deltagamma nAChRs. In functional in vitro cation flux assays, A-85380 is a potent and full agonist. A-85380 has a broad-spectrum analgesic profile with efficacy in acute, persistent, and neuropathic pain models. As demonstrated using selective nAChR antagonists or alpha(4) antisense, the alpha(4)beta(2) nAChR mediates the analgesic effects of A-85380. Interestingly, the site of action depends upon the type of pain as antinociception is mediated by descending inhibition into the spinal cord whereas anti-allodynia in neuropathic pain is mediated at both central and peripheral sites. Radiolabelled forms of A-85380 have been developed and shown to be safe for use in vivo in humans. In clinical studies using positron and photon emission tomography, marked decreases in alpha(4)beta(2) nAChRs have been seen in patients with Parkinson's and Alzheimer's disease. Although not developed as a therapeutic agent, A-85380 has proven to be an important component in the development of novel nAChR ligands for the treatment of pain and other disorders.
机译:A-85380 [3-(2(s)-氮杂环丁烷基甲氧基)吡啶]是一种神经元烟碱型乙酰胆碱受体(nAChR)激动剂,在临床前和临床研究中一直是研究nAChRs功能的有用工具。在nAChR亚型中,A-85380显示出alpha(4)beta(2)与alpha(7)或alpha(1)beta(1)deltagamma nAChRs的选择性。在功能性体外阳离子通量测定中,A-85380是有效的全激动剂。 A-85380具有广谱镇痛作用,可用于急性,持续性和神经性疼痛模型。如使用选择性nAChR拮抗剂或alpha(4)反义物所证明的,alpha(4)beta(2)nAChR介导A-85380的镇痛作用。有趣的是,作用部位取决于疼痛的类型,因为抗伤害感受是通过抑制对脊髓的抑制作用来介导的,而神经性疼痛中的抗异常性疼痛则是在中枢和周围部位介导的。已经开发出放射性标记的A-85380形式,并显示在人体中使用是安全的。在使用正电子和光子发射断层扫描的临床研究中,帕金森氏病和阿尔茨海默氏病患者的alpha(4)beta(2)nAChRs明显减少。尽管尚未开发为治疗剂,但已证明A-85380是开发新型nAChR配体以治疗疼痛和其他疾病的重要组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号